Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 4 HPR; HPR; MCNR 1967; RT-101; ST-602

Latest Information Update: 23 Jan 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ortho-McNeil
  • Developer Ortho-McNeil; ReVision Therapeutics
  • Class Antineoplastics; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Plasma retinol-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Basal cell cancer; Bladder cancer; Breast cancer; Dry age-related macular degeneration; Glioma; Neuroblastoma; Prostate cancer; Rheumatoid arthritis

Most Recent Events

  • 23 Jan 2015 Discontinued - Phase-II for Dry age-related macular degeneration in USA (PO)
  • 18 Oct 2010 Final efficacy data from a phase IIb trial in Age-related macular degeneration released by ReVision Therapeutics
  • 15 Apr 2009 Fenretinide received Fast Track designation for Age-related macular degeneration [PO] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top